Adalimumab
| EAS | Nº pacientes | Respuesta terapéutica n (%) |
Efectos adversos n (%) |
Mortalidad n (%) |
|---|---|---|---|---|
Behçet |
9 |
9 (100%) |
3 (33%) |
0 (0%) |
Sarcoidosis |
3 |
3 (100%) |
0 (0%) |
0 (0%) |
Still adulto |
2 |
1 (50%) |
0 (0%) |
0 (0%) |
Dermatomiositis |
1 |
1 (100%) |
0 (0%) |
0 (0%) |
| Sarcoidosis | 1 |
1(100%) |
0(0%) |
0(0%) |
Esclerosis sistémica |
1 |
0 (0%) |
1 (100%) |
0 (0%) |
Horton |
1 |
1 (100%) |
0 (0%) |
0 (0%) |
TOTAL |
17 |
15 (88%) |
4 (24%) |
0(0%) |